Introduction
============

*Pseudomonas aeruginosa* is a versatile Gram-negative pathogenic bacterium, that can cause various infections in human ([@B15]; [@B11]). During infection, *P. aeruginosa* produces multiple virulence factors to facilitate colonization ([@B61]; [@B33]; [@B23]; [@B45]). Meanwhile, its highly intrinsic antibiotic resistance and biofilm forming ability greatly hinder the eradication of this pathogen ([@B25]). In patients suffering from cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), *P. aeruginosa* caused chronic respiratory infections are responsible for most of the morbidity and mortality ([@B59]; [@B60]). Intensive antibiotic treatment has been used to maintain the lung function and extend lifespan of the patients ([@B16]). However, the increasing antibiotic resistance has been compromising clinical efficacy of traditional antibiotics. Thus, alternatives or unconventional usage of the antibiotics are urgently needed ([@B9]; [@B56]; [@B27]).

The macrolide antibiotic azithromycin (AZM) provides a paradigmatic example of an unconventional antibacterial drug for *P. aeruginosa* treatment. Although, *P. aeruginosa* is highly resistance to macrolides owning to its low outer membrane permeability and the resistance-nodulation-cell division (RND) systems, AZM treatment benefits patients suffering from both intermittent and chronic *P. aeruginosa* infections ([@B62]; [@B44]; [@B8]; [@B72]; [@B2]; [@B51]). AZM has been shown to have immunomodulatory activity, which attenuates the inflammatory response and promotes macrophage phagocytic activity ([@B39]; [@B73]; [@B77]). Furthermore, AZM exhibits bactericidal effect on stationary growth phase *P. aeruginosa* cells ([@B47], [@B48]; [@B26]; [@B34]; [@B71]; [@B21]). And sub-inhibitory concentrations of AZM suppress biofilm formation, motility, and production of multiple virulence factors, including proteases, pyocyanin, exotoxin A, phospholipase C (PLC), exopolysaccharides, and other quorum-sensing (QS) regulated genes in *P. aeruginosa* ([@B50], [@B49]; [@B75]; [@B18]; [@B20]). The AZM-mediated killing of stationary-phase bacterial cells and reduced expression of QS-regulated virulence factors require interaction between AZM and ribosome ([@B34]). AZM binds in the nascent peptide exit tunnel (NPET), resulting in ribosome stalling and depletion of the intracellular pools of aminoacyl-tRNAs ([@B47], [@B48]; [@B34]; [@B71]; [@B21]). The effects of AZM on *P. aeruginosa* can be counteracted by over expression of ErmBP or a peptidyl-tRNA hydrolase, which blocks the interaction between AZM and ribosome by modifying the 23S rRNA or increases the intracellular aminoacyl-tRNA level, respectively ([@B34]; [@B21]). However, how *P. aeruginosa* response to AZM treatment remains unclear. Understanding the mechanisms that *P. aeruginosa* uses to counteract AZM treatment may provide clues to enhance AZM-mediated virulence inhibitory and bacterial killing effects.

A large RNA helicase family named DExD/H box helicases are characterized by a conserved DExD/H box sequence ([@B14]; [@B43]), and play crucial roles in rRNA processing, translation initiation, and mRNA decay ([@B29]; [@B42]). In addition, the DExD/H box helicases have been shown to participate in bacterial responses to various stresses, such as cold shock, pH, osmotic, and oxidative stresses ([@B54]). And several DEAD family RNA helicases, which belong to a specific subfamily of DExD/H box helicases, have been shown to regulate virulence factors in *Escherichia coli*, *Borrelia burgdorferi*, *Staphylococcus aureus*, *Listeria monocytogenes*, and *P. aeruginosa* ([@B35]; [@B63], [@B64]; [@B53]; [@B4]; [@B28]). The pleiotropic functions of DExD/H box family RNA helicases intrigued us to suspect that they might be involved in the bacterial response to AZM treatment. In this study, we found that deficiency in a DEAH box helicase, PA3297, renders *P. aeruginosa* more susceptible to the killing and virulence suppression by AZM. Our results suggest that the expression of PA3297 was up regulated in the presence of AZM, which might promote 23S rRNA maturation to counteract the inhibitory effect of AZM on protein elongation.

Materials and Methods {#s1}
=====================

Strains and Plasmids
--------------------

The bacterial strains and plasmids used in this study are listed in **Table [1](#T1){ref-type="table"}** ([@B67]; [@B24]; [@B12]; [@B41]). The *E. coli* strains DH5α, S17-1 and *P. aeruginosa* strains were routinely cultured in Luria-Bertani (LB) broth at 37°C. Antibiotics were used at the following concentrations: for *E. coli*, ampicillin 100 μg/ml, tetracycline 10 μg/ml, and gentamicin 10 μg/ml; for *P. aeruginosa*, carbenicillin 150 μg/ml, tetracycline 50 μg/ml, and gentamicin 50 μg/ml.

###### 

Bacterial strains and plasmids used in this study.

  Strain or plasmid               Description^a^                                                                                                                          Reference or origin
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  ***E. coli* strains**                                                                                                                                                   
  DH5α                            F^-^, φ80d*lacZ*Δ*M15*,Δ*(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(r~k~*^-^*,m~k~^+^), phoA, supE44, λ*^-^*, thi1, gyrA96, relA1*   TransGen
  S17-1                           *thi pro hsdR recA* Tra^+^                                                                                                              [@B67]
  ***P. aeruginosa* strains**                                                                                                                                             
  PA14                            Wild type *Pseudomonas aeruginosa* strain PA14                                                                                          [@B41]
  PA0426::Tn                      PA14 with a transposon inserted at PA0426                                                                                               [@B41]
  PA0455::Tn                      PA14 with a transposon inserted at PA0455                                                                                               [@B41]
  PA2840::Tn                      PA14 with a transposon inserted at PA2840                                                                                               [@B41]
  PA3002::Tn                      PA14 with a transposon inserted at PA3002                                                                                               [@B41]
  PA3272::Tn                      PA14 with a transposon inserted at PA3272                                                                                               [@B41]
  PA3297::Tn                      PA14 with a transposon inserted at PA3297                                                                                               [@B41]
  PA3308::Tn                      PA14 with a transposon inserted at PA3308                                                                                               [@B41]
  PA3861::Tn                      PA14 with a transposon inserted at PA3861                                                                                               [@B41]
  PA3950::Tn                      PA14 with a transposon inserted at PA3950                                                                                               [@B41]
  ΔPA3297                         PA14 with PA3297 in frame deletion                                                                                                      This study
  ΔPA3297/att7::PA3297            PA14 ΔPA3297 with insertion of a single copy of PA3297 driven by its own promoter at attTn7 sites                                       This study
  ΔPA3297/att7::PA3297 K101A      PA14 ΔPA3297 complemented with a single copy of PA3297 acquired a lysine101 mutation to alanine                                         This study
  ΔPA3297/att7::PA3297 D192A      PA14 ΔPA3297 complemented with a single copy of PA3297 acquired an aspartate192 mutation to alanine                                     This study
  ΔPA3297/att7::PA3297SAT224AAA   PA14 ΔPA3297 complemented with a single copy of PA3297 acquired a serine224 and threonine226 mutation to alanines                       This study
  **Plasmids**                                                                                                                                                            
  pEX18Tc                         Broad-host-range gene replacement vector; *sacB* TET^r^                                                                                 [@B24]
  pUC18t-mini-Tn7T-Gm             For gene insertion in chromosome; GEN^r^                                                                                                [@B12]
  pTNS3                           Helper plasmid                                                                                                                          [@B12]
  pFLP2                           Source of Flp recombinase; *sacB*, AMP^r^/CAR^r^                                                                                        [@B24]
  pTH1501                         pEX18Tc::ΔPA3297; TET^r^                                                                                                                This study
  pTH1502                         PA3297 gene of PA14 on pUC18T-Mini-Tn7T-Gm with its own promoter; GEN^r^                                                                This study
                                                                                                                                                                          

a

AMP

r

, ampicillin resistant; TET

r

, tetracycline resistant; GEN

r

, gentamicin resistance; CAR

r

, carbenicillin resistant.

DNA Methods
-----------

DNA manipulations were performed according to standard protocols or following manufacturers' instructions ([@B24]; [@B82]; [@B12]). The pEX18Tc::ΔPA3297 (pTH1501) was constructed by cloning the 1002-bp upstream and 964-bp downstream fragments of PA3297 coding region into the KpnI-HindIII sites of plasmid pEX18Tc. The fragments were amplified from the PA14 chromosome with primers PA14-UPA3297-FF, PA14-UPA3297-FR, PA14-DPA3297-FF, and PA14-DPA3297-FR (**Table [2](#T2){ref-type="table"}**), respectively. Deletion of the PA3297 gene was confirmed by PCR with primers PA14-PA3297-FF and PA14-PA3297-FR (**Table [2](#T2){ref-type="table"}**). For the complementation of PA3297, the PA3297 gene was amplified from the PA14 chromosome by PCR with the primers PA14-PA3297-FF and PA14-PA3297-FR (**Table [2](#T2){ref-type="table"}**). The PCR product was ligated into the EcoRI- SacI sites of pUC18t-mini-Tn7T-Gm, resulting in pTH1502. The plasmid was introduced into the ΔPA3297 mutant by electroporation, along with the helper plasmid pTNS3 ([@B12]). Insertion of the PA3297 gene into the chromosome was confirmed by PCR with primers P~Tn7R~ and P~glmS-down~ (**Table [2](#T2){ref-type="table"}**; [@B12]). The site-directed mutagenesis was performed as previously described ([@B82]). The mutation sites were chosen based on the conserved critical residues of other bacterial DExD-box proteins ([@B35]; [@B14]). Briefly, PCR amplification was performed with pTH1502 as template and with primers listed in **Table [2](#T2){ref-type="table"}**, for K101A, D192A, and SAT224-226AAA mutations, respectively. The PCR products were treated by DpnI for 3 h at 37°C and purified before transformation. The correctly mutated clones were identified by DNA sequencing.

###### 

Primers used in this study.

  Primers^a^                                                             Nucleotide sequence (53)^b^
  ---------------------------------------------------------------------- --------------------------------------------------------------------------------------
  **Cloning of upstream and downstream fragments for PA3297 deletion**   
  PA14-UPA3297-FF                                                        GAAAGC[GGTACC]{.ul}GAAGTAAGTCCGCCGTTGCC (Kpn I)
  PA14-UPA3297-FR                                                        CAGCTT[TCTAGAG]{.ul}GTGCTGTCGTCGCTCTGGT (Xba I)
  PA14-DPA3297-FF                                                        TTGCAG[TCTAGA]{.ul}CGCTGGATGCTGGAGGAGTA (Xba I)
  PA14-DPA3297-FR                                                        CGCCGG[AAGCTT]{.ul}CACCGAGCAGTGGCTGAAGAC (Hind III)
  **Cloning of gene PA3297 for complementation**                         
  PA14-PA3297-FF                                                         TGAAGA[GAATTC]{.ul}GCCAGAAGTAAGTCCGCCGTTGCC (EcoR I)
  PA14-PA3297-FR                                                         CACCGG[GAGCTC]{.ul}CGACCAGACCGACCTGTTCTTCACCAT (Sac I)
  P~Tn7R~                                                                CACAGCATAACTGGACTGATTTC
  P~glmS-down~                                                           GCACATCGGCGACGTGCTCTC
  **Primers used for site-directed mutagenesis of PA3297**               
  PA3297-K101A-FF                                                        GCGAGACCGGCTCGGGC![](fmicb-07-00317-i001.jpg)ACCACCCAG
  PA3297-K101A-FR                                                        T![](fmicb-07-00317-i002.jpg)GCCCGAGCCGGTCTCGCCGGCGATC
  PA3297-D192A-FF                                                        TACGACACGCTGATCGTC![](fmicb-07-00317-i003.jpg)GAAGCCCAC
  PA3297-D192A-FR                                                        C![](fmicb-07-00317-i004.jpg)GACGATCAGCGTGTCGTAGCGCTCCAG
  PA3297-SAT224-226AAA-FF                                                GCTGATCATCACC![](fmicb-07-00317-i001.jpg)GCG![](fmicb-07-00317-i003.jpg)ATCGACCTGGAG
  PA3297-SAT224-226AAA-FR                                                T![](fmicb-07-00317-i004.jpg)CGC![](fmicb-07-00317-i002.jpg)GGTGATGATCAGCTTCAGGTCC
  **RT-qPCR primers for gene expression measurements**                   
  23S-R-FF                                                               AAAGATAACCGCTGAAAG
  23S-R-FR                                                               CTATCAACGTCGTAGTCT
  5S-R-FF                                                                CGAACTCAGAAGTGAAAC
  5S-R-FR                                                                CTTGACGATGACCTACTC
  23S-5S-R-FF                                                            GTACTAATTGCCCGTGAG
  23S-5S-R-FR                                                            GTTCCAACGCTCTATGAT
                                                                         

a

The direction of the primer is indicated at the end of the primer designation as follows: FF for forward and FR for reverse.

b

The solid underlines are the sites of listed restriction enzymes; the dotted underlines are the sites for mutagenesis, with all the residues changed into alanine.

Assay for Pyocyanin Production
------------------------------

The pyocyanin concentration was determined as described previously ([@B17]). Briefly, 1 ml supernatant from each 24-h-old bacteria culture grown in the absence or presence of AZM was extracted with 0.5 ml of chloroform. Then, 0.4 ml solution from the lower organic phase was re-extracted into 0.3 ml of 0.2 N HCl to give a pink solution, whose absorbance was measured at 520 nm. Concentrations of pyocyanin (mg/ml) were calculated by multiplying the OD~520~ by 32.01 ([@B36]).

Antibiotic Susceptibility Assay
-------------------------------

Minimum inhibitory concentrations (MICs) of *P. aeruginosa* to antimicrobial agents were determined by serial twofold broth dilution in LB medium, as described previously ([@B30]). MICs were recorded as the lowest concentration of antibiotic inhibiting visible growth after 24 h of incubation at 37°C.

Stationary-Phase Bacterial Cell Killing Assay
---------------------------------------------

The killing assay was performed as described previously ([@B34]). Briefly, bacteria were inoculated in LB medium and grown for 16 h at 37°C. The culture of each strain was diluted to an OD~600~ of 0.05 and cultured at 37°C. After reaching stationary phase (OD~600~, 3.0), indicated concentrations of AZM were added to the 2-ml aliquots of the cultures. Then the bacteria were cultured for 20--22 h at 37°C. The viable bacterial numbers were determined by serial dilution and plating on drug-free LB agar plates. The survival rate of each strain was calculated as live bacterial number in AZM treated sample divided by the bacterial number of the corresponding untreated sample.

Biofilm Tolerance to AZM
------------------------

The biofilm resistance was measured as previously described with minor modifications ([@B7]; [@B6]; [@B40]). Briefly, overnight bacterial cultures were diluted to an OD~600~ of 0.025. 150 μl of the bacteria were incubated in each well of a 96-well plate at 37°C without agitation ([@B10]). After 24 h, the planktonic bacteria were discarded by aspiration. Then, the biofilms were treated with 150 μl LB medium containing indicated concentrations of AZM for 2 h. The medium in each well was replaced with fresh LB medium, and subjected to sonication at a frequency of 40 kHz, with a power output of 300 W, at 37°C for 5 min. The live bacteria were enumerated by serial dilution and plating.

Growth Assay
------------

Overnight culture of each strain was diluted into fresh LB (150 μl) to an OD~600~ of 0.05 in each well of a 96-well plate without or with different concentrations of AZM. The plate was incubated at 37°C with constant agitation ([@B37]; [@B22]). The bacterial growth was monitored by measuring the OD~600~ every 30 min for 12 h by a Varioskan Flash microplate reader (Thermo Electron Corporation).

H~2~O~2~ Susceptibility Assay
-----------------------------

Overnight cultures of the *P. aeruginosa* strains were diluted to an OD~600~ of 0.05 and cultured at 37°C. When the OD~600~ reached 0.3 (about 1.5--2 h later), AZM (0.5 μg/ml) was added if needed. When the OD~600~ reached 2.0 (about 3 h later), bacteria from 500 μl culture were collected and washed twice with phosphate buffered saline (PBS). Then the bacteria were resuspended in PBS with or without 10% H~2~O~2~ and incubated for 15 min. The live bacterial numbers were determined by serial dilution and plating.

Motility Assay
--------------

The swarming motility was tested on modified M9 medium plates supplemented with 0.2% glucose, 1 mM MgSO~4~, and 0.05% glutamate as the nitrogen source. 0.5% agar was used for solidification. Two microliters of exponential growth phase *P. aeruginosa* was deposited on the plates, then incubated for 18 h at 37°C ([@B34]).

Total RNA Isolation and Quantitative Real-Time PCR
--------------------------------------------------

Overnight cultures of *P. aeruginosa* strain PA14 and ΔPA3297 were diluted into fresh LB medium to an OD~600~ of 0.05. The bacteria were grown at 37°C with agitation (200 rpm). When the OD~600~ reached 0.3 (about 1.5--2 h later), AZM was added to reach indicated concentrations. Samples were harvested when the OD~600~ reached 2.0 (about 3 h later; [@B69]). Total RNA was isolated with an RNeasy Minikit (Tiangen Biotech). The cDNA from each RNA sample was synthesized with reverse transcriptase and random primers (Takara). Real-time PCR was performed with SYBR premix Ex Taq (Roche). The conserved hypothetical protein coding gene PA1769 was used as an internal control ([@B70]). The primers used in quantitative real-time PCR were listed in **Table [2](#T2){ref-type="table"}**, with a designation of "RT-qPCR."

Statistical Analysis
--------------------

When indicated, Student's *t*-test (two-tailed) was used to determine whether the deletion of PA3297 resulted in any significant differences compared to the wild-type cells treated with the same concentrations of AZM.

Results
=======

Deficiency of PA3297 Intensifies the Effects of AZM on Pyocyanin Production
---------------------------------------------------------------------------

As pyocanin production is suppressed by AZM ([@B50], [@B49]; [@B75]; [@B18]; [@B20]), which can be easily observed and quantified, we used this phenotype to test whether DExD/H box RNA helicases are involved in bacterial response to AZM treatment. There are 17 DExD/H box RNA helicases in the genome of *P. aeruginosa* strain PA14 ([www.pseudomonas.com](http://www.pseudomonas.com); [@B81]). There are nine DExD/H box helicase mutants in the non-redundant PA14 transposon mutants library, however, the other eight DExD/H box helicase mutants are not available (**Table [1](#T1){ref-type="table"}**; [@B41]; [@B9]). Thus, we examined pyocyanin production of the available mutants in the absence and presence of AZM at an OD~600~ of 2.0. A PA3297::Tn mutant displayed a significant decrease in pyocyanin production in the presence of AZM, whereas no difference was observed in the absence of AZM (**Figure [1A](#F1){ref-type="fig"}**). To confirm the role of PA3297, we generated an in frame deletion of PA3297 in PA14. The wild type PA14 and the ΔPA3297 mutant were grown in the absence or presence of 2, 5, or 10 μg/ml AZM. When the bacteria reached same density (OD~600~ of 2.0), we measured the pyocyanin levels. AZM inhibited the production of pyocyanin in the wild type strain in a dose dependent manner. However, the production of pyocyanin by the mutant was repressed more severely in the presence of AZM at all the tested concentrations (**Figure [1B](#F1){ref-type="fig"}**). Complementation with a PA3297 gene restored the production of pyocyanin (**Figure [1B](#F1){ref-type="fig"}**).

![**Mutation of PA3297 intensified the AZM mediated inhibition of pyocyanin production. (A)** Wild type PA14 and the mutants of DExD/H box helicases were grown to an OD~600~ of 2.0 in the absence or presence of 5 μg/ml AZM at 37°C and the pyocyanin concentrations were measured. **(B)** Bacteria of wild type PA14, ΔPA3297 mutant and the complementation strain were grown in the absence or presence of 2, 5, or 10 μg/ml AZM. When the OD~600~ reached 2.0, the pyocyanin concentrations were measured. The values are the means of three replicates and the error bars display the standard deviations. "ND" standards for "not detected." ^∗^*p* \< 0.05 compared to PA14 or the complemented strain by student's *t*-test.](fmicb-07-00317-g001){#F1}

Increased Killing of the ΔPA3297 Mutant by AZM
----------------------------------------------

Stationary growth phase *P. aeruginosa* cells are susceptible to AZM ([@B47], [@B48]; [@B26]; [@B34]; [@B71]; [@B21]). To test whether mutation of PA3297 renders higher susceptibility, we performed the stationary-phase cells killing assay as previously described ([@B26]; [@B34]; [@B21]). Stationary-phase cells of PA14, the ΔPA3297 mutant and the complementation strain were subjected to treatment with AZM at the concentrations of 2, 5, and 10 μg/ml. As shown in **Figure [2A](#F2){ref-type="fig"}**, the AZM-mediated killing of the ΔPA3297 mutant was significantly increased at all of the AZM concentrations tested. The most significant difference was observed at the concentration of 10 μg/ml, where the survival rate of the mutant was approximately 1% of those of the wild type and complemented strains. In addition, the ΔPA3297 mutant was more susceptible to another macrolid antibiotic, erythromycin, with a fourfold lower MIC compared to the wild type strain PA14 (**Table [3](#T3){ref-type="table"}**).

![**Increased killing of the ΔPA3297 mutant by AZM. (A)** AZM-mediated killing of wild type PA14, the ΔPA3297 mutant and the mutant complemented with wild type or the mutated PA3297. Stationary-phase bacteria were treated with 2, 5, or 10 μg/ml AZM for 20 h at 37°C. The numbers of live bacteria were determined by serial dilution and plating. **(B)** AZM-mediated killing of biofilm. 24-h-old biofilms formed by wild type PA14, the ΔPA3297 mutant and the complemented strain were treated with 5 μg/ml, 10 μg/ml AZM or not for 2 h. Bacteria in the biofilm were dissociated from the wells by gentle sonication. The viable bacteria were determined by serial dilution and plating. The averages and associated standard deviations from three replicates are shown. ^∗^*p* \< 0.05 compared to PA14 or the complemented strain by student's *t*-test.](fmicb-07-00317-g002){#F2}

###### 

Bacterial susceptibilities to macrolides and lincosamides.

  Strain                              MIC (μg/ml)^a^                   
  ----------------------------------- ---------------- ----- --------- ------
  PA14                                300              400   12800     4800
  ΔPA3297                             75               100   3200      2400
  ΔPA3297/att7::PA3297                300              400   \>12800   9600
  ΔPA3297/att7::PA3297 K101A^b^       75               100   6400      1600
  ΔPA3297/att7::PA3297 D192A^b^       75               100   3200      2400
  ΔPA3297/att7::PA3297 SAT224AAA^b^   75               100   6400      2400
                                                                       

a

ERY, erythromycin; AZM, azithromycin; LIN, lincomycin; CLI, clindamycin.

b

Mutants with single or triple amino acid changes.

Next, we tested the susceptibility of the ΔPA3297 mutant to lincosamides, whose bactericidal mechanism is similar to macrolides ([@B76]; [@B79]). Indeed, mutation in PA3297 increased the bacterial susceptibility to lincomycin and clindamycin (**Table [3](#T3){ref-type="table"}**). However, no increase of susceptibility was observed to other antibiotics, including ciprofloxacin, carbenicillin, meropenem, tetracycline, tobramycin, kanamycin, chloramphenicol, or polymyxin B (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). These results suggest that PA3297 plays an important role in the resistance against antibiotics targeting the peptide exit tunnel of ribosome.

PA3297 is a putative RNA helicase belonging to the DEAH-box family proteins, which are characterized by the presence of seven to nine conserved motifs ([@B74]). In the *E. coli* RNA helicases DbpA and HrpA, the conserved residues GETGSGKT in motifI, DEAH in motifII, and SAT in motifIII have been shown to be required for interaction with and hydrolysis of NTP ([@B35]; [@B42]). To determine whether these critical residues within motifs I, II, and III are important for PA3297 in the resistance to macrolides and lincosamides, we altered the residues by site-directed mutagenesis. Specifically, the K101 in motif I or the D167 in motif II was mutated to alanine. The S224 and T226 in motif III were both replaced with alanine. Each mutated PA3297 was transferred into the ΔPA3297 mutant and the susceptibility to antibiotics was tested. None of the mutated PA3297 was able to restore the survival rate of the mutant (**Figure [2A](#F2){ref-type="fig"}**). In addition, the mutated PA3297 was unable to restore the resistance of the ΔPA3297 mutant to macrolides, lincomycin, and clindamycin (**Table [3](#T3){ref-type="table"}**). These results suggest that the RNA helicase function of PA3297 is required for its role in the resistance to macrolides and lincosamides.

Clinically, AZM has been used in the treatment of chronic *P. aeruginosa* infection ([@B62]; [@B8]), which is characterized by biofilm formation ([@B68]). The biofilm is notorious for high antibiotic tolerance, which severely hinders eradication of the bacteria ([@B46]; [@B9]). We suspected that mutation of PA3297 might increase the killing efficacy of AZM on the biofilm. Indeed, the survival rates of the ΔPA3297 mutant in biofilm were lower than those of the wild type PA14 at various AZM concentrations, which were restored by complementation with a wild type PA3297 (**Figure [2B](#F2){ref-type="fig"}**).

Mutation of PA3297 Increases the Bacterial Susceptibility to Hydrogen Peroxide in the Presence of AZM
-----------------------------------------------------------------------------------------------------

It has been shown that AZM treatment impairs the oxidative stress response in *P. aeruginosa* ([@B52]), which intrigued us to test whether mutation of PA3297 leads to further impairment. The H~2~O~2~ susceptibility assay was performed in the presence of 0.5 μg/ml AZM, as the growth rates of wild type PA14 and the ΔPA3297 mutant were similar at this concentration of AZM (**Supplementary Figure [S1](#SM2){ref-type="supplementary-material"}**). The wild type PA14, ΔPA3297 mutant and the complemented strain were grown without or with AZM to an OD~600~ of 2.0, and then treated with 10% H~2~O~2~ for 15 min. In the presence of AZM, the ΔPA3297 mutant was more susceptible to H~2~O~2~ than the wild type and complemented strains, whereas no difference was observed in the absence of AZM (**Figure [3](#F3){ref-type="fig"}**). These results suggest that PA3297 is involved in the bacterial oxidative stress response in the presence of AZM.

![**Hydrogen peroxide (H~2~O~2~) mediated killing of bacteria.** PA14, the ΔPA3297 mutant and complemented strain were grown at 37°C in the absence or presence of 0.5 μg/ml AZM to an OD~600~ of 2.0. Bacteria were collected and washed with PBS. Then the bacteria were incubated in PBS with or without 10% H~2~O~2~ for 15 min. The live bacterial numbers were determined by serial dilution and plating. ^∗^*p* \< 0.05 compared to PA14 or the complemented strain by student's *t*-test.](fmicb-07-00317-g003){#F3}

Mutation of PA3297 Intensifies the Inhibitory Effect of AZM on Swarming Motility
--------------------------------------------------------------------------------

Besides oxidative stress response, AZM suppresses swarming motility ([@B75]; [@B34]; [@B21]). Same numbers of wild type PA14 and the ΔPA3297 mutant were inoculated on the plates containing various concentrations of AZM. As shown in **Figure [4](#F4){ref-type="fig"}**, 10 μg/ml AZM suppressed the swarming motility of wild type PA14 obviously, whereas the lower concentrations of AZM showed no inhibitory effect. However, starting from 2 μg/ml, AZM suppressed the swarming motility of the ΔPA3297 mutant in a dose dependent manner. Complementation with a PA3297 gene restored the swarming motility in the presence of AZM (**Figure [4](#F4){ref-type="fig"}**).

![**Bacterial swarming motility.** PA14 (i), the ΔPA3297 mutant (ii) and the complemented strain (iii) were inoculated on plates containing indicated concentrations of AZM.](fmicb-07-00317-g004){#F4}

Interaction between AZM and Ribosome Induces the Expression of PA3297
---------------------------------------------------------------------

Our results so far suggested that PA3297 is involved in the bacterial response to AZM treatment. To test whether the expression of PA3297 is induced by AZM treatment, wild type PA14 was grown in the absence or presence of AZM at various concentrations and the relative RNA levels of PA3297 were determined by real time PCR. Indeed, the expression of PA3297 was induced by AZM (**Figure [5A](#F5){ref-type="fig"}**). However, overexpression of PA3297 in wild type PA14 did not further increase the bacterial tolerance to AZM (**Table [4](#T4){ref-type="table"}**). We suspect that since the bacteria at exponential growth phase are highly resistant to macrolides and lincosamides, overexpression of PA3297 might not further increase the resistance significantly in the MIC test. Another possibility is that with the endogenous up regulation of PA3297, additional expression of PA3297 might be redundant.

![**Expression of PA3297 in the presence of AZM. (A)** Wild type PA14 was grown to an OD~600~ of 0.3 in LB medium. The bacteria were grown further in the absence or presence of 2, 5, or 10 μg/ml AZM. When the OD~600~ reached 2.0, total bacterial RNA was isolated and the mRNA levels of PA3297 were determined with real time PCR. ^∗^*p* \< 0.05 compared to bacteria in the absence of presence of 2 or 5 μg/ml AZM by student's *t*-test. **(B)** PA14 harboring pMMB67EH or the ErmC over expressing plasmid (pMMB67EH-*ermC*) was grown at 37°Cin the absence of AZM. When the OD~600~ reached 0.3, 1 mM IPTG was added to the medium. Meanwhile, no AZM or AZM at the final concentration of 10 μg/ml was added to the medium. At the OD~600~ of 2.0, total RNA was isolated and the mRNA levels of PA3297 were determined with real time PCR. The mRNA levels of *lacI* from the plasmid were used as internal control. ^∗^*p* \< 0.05 compared to PA14/pMMB67EH by student's *t*-test.](fmicb-07-00317-g005){#F5}

###### 

Bacterial susceptibilities to macrolides and lincosamides.

  Strain                  MIC (μg/ml)^a^                   
  ----------------------- ---------------- ----- --------- ---------
  PA14/pMMB67EH           600              200   12800     12800
  PA14/pMMB67-PA3297      600              200   12800     6400
  PA14/pMMB67-*ermC*      2400             800   \>12800   \>12800
  ΔPA3297/pMMB67EH        75               50    6400      3200
  ΔPA3297/pMMB67-PA3297   300              200   12800     3200
  ΔPA3297/pMMB67-*ermC*   2400             400   \>12800   \>12800
                                                           

a

ERY, erythromycin; AZM, azithromycin; LIN, lincomycin; CLI, clindamycin.

[@B34] previously demonstrated that ribosome is the only target of AZM in bacteria. To test whether the induction of PA3297 is caused by the interaction between AZM and ribosome, we performed the ribosomal protection assay by overexpressing ErmC, a 23S rRNA methylase that blocks the binding of macrolide antibiotics to the NPET ([@B34]; [@B38]). In the presence of 10 μg/ml AZM, the growth speed of the ErmC overexpressing strain was similar with that of the wild type strain containing an empty vector. However, overexpression of ErmC abolished the induction of PA3297 by AZM (**Figure [5B](#F5){ref-type="fig"}**). In addition, antibiotics in the other categories, including ciprofloxacin, tobramycin, and carbenicillin did not affect the expression level of PA3297 (**Supplementary Figure [S2](#SM3){ref-type="supplementary-material"}**). These results suggest that the expression of PA3297 is regulated in response to AZM-mediated ribosome stalling.

Ribosome Protection Rescues the ΔPA3297 Mutant from AZM-Mediated Hyperlethality
-------------------------------------------------------------------------------

So far, we have demonstrated that the expression of PA3297 is induced by AZM and that mutation of PA3297 renders *P. aeruginosa* hypersusceptible to AZM. These results suggest that PA3297 might play a role in counteracting the detrimental effects caused by the interaction between AZM and ribosome ([@B34]; [@B21]). Thus, ribosome protection should be able to increase the tolerance of the ΔPA3297 mutant to AZM. Indeed, overexpression of ErmC increased both the growth speed and the survival rate of the ΔPA3297 mutant when treated with 10 or 40 μg/ml AZM (**Supplementary Figure [S3](#SM4){ref-type="supplementary-material"}**, **Figure [6](#F6){ref-type="fig"}**). In addition, overexpression of ErmC increased the MICs of both wild type PA14 and the ΔPA3297 mutant to AZM, erythromycin, lincomycin and clindamycin (**Table [4](#T4){ref-type="table"}**). Mutation of PA3297 did not increase the bacterial susceptibility to a variety of other antibiotics (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). These results suggest a specific role of PA3297 in responding to lincosamides and macrolides.

![**Effects of Ribosome protection on the AZM mediated killing of the ΔPA3297 mutant.** Wild type PA14 or the ΔPA3297 mutant harboring pMMB67EH or pMMB67EH-*ermC* was grown to an OD~600~ of 0.5 when 1 mM IPTG was added to the medium. When the OD~600~ reached 2.0, the bacteria were treated without or with 10 or 40 μg/ml AZM for 20 h at 37°C. The numbers of live bacteria were determined by serial dilution and plating. ^∗^*p* \< 0.05 compared to the ΔPA3297 mutant harboring pMMB67EH by student's *t*-test.](fmicb-07-00317-g006){#F6}

Deficiency in PA3297 Compromises rRNA Processing in the Presence of AZM
-----------------------------------------------------------------------

Studies in *E. coli* demonstrated that the DExD/H box play crucial roles in rRNA processing ([@B29]; [@B42]). Therefore, we suspected that the up regulated PA3297 might participate in rRNA maturation, which facilitates ribosome biogenesis to compensate for AZM inactivated ribosome. The rRNA coding region in the chromosome of *P. aeruginosa* PA14 is shown in **Supplementary Figure [S4](#SM5){ref-type="supplementary-material"}**. To examine the processing of the rRNA transcript, we designed real-time PCR primers to analyze the total 23S and 5S rRNA levels as well as primers across the 23S and 5S rRNA coding region to analyze the level of unprocessed rRNA (**Supplementary Figure [S4](#SM5){ref-type="supplementary-material"}**). In wild type PA14, AZM at the concentrations of 5 and 10 μg/ml reduced the 23S and 5S rRNA levels (**Figures [7A,B](#F7){ref-type="fig"}**), and 10 μg/ml AZM slightly increased the unprocessed 23S-5S rRNA level (**Figure [7C](#F7){ref-type="fig"}**). In the absence of AZM, the total 23S and 5S rRNA levels were higher in the ΔPA3297 mutant than those in the wild type strain (**Figures [7A,B](#F7){ref-type="fig"}**), whereas the unprocessed 23S-5S levels were similar between the mutant and wild type strain. Interestingly, treatment with 10 μg/ml AZM resulted in a higher level of unprocessed 23S-5S rRNA in the ΔPA3297 mutant (**Figure [7C](#F7){ref-type="fig"}**), although its total 23S and 5S rRNA levels were lower than those in the wild type strain (**Figures [7A,B](#F7){ref-type="fig"}**).

![**Effects of AZM on the processing of rRNA.** PA14, the ΔPA3297 mutant and the complemented strain were grown at 37°C in the absence of AZM. When the OD~600~ reached 0.3, AZM (0, 5, and 10 μg/ml) was added. Total RNA was harvested when the OD~600~ reached 2.0. The levels of total 23S **(A)**, 5S **(B)**, and unprocessed 23S-5S rRNA **(C)** were determined by real time PCR. The mRNA levels of PA1769 were used as an internal control. ^∗^*p* \< 0.05 compared to PA14 by student's *t*-test.](fmicb-07-00317-g007){#F7}

Next, we calculated the percentages of unprocessed 23S-5S rRNA in wild type PA14 and the ΔPA3297 mutant with or without AZM treatment. Standard curves were generated to determine the amplification efficiencies of the primer pairs for the detection of total 23S, 5S and unprocessed 23S-5S rRNA levels in real time PCR (**Supplementary Figure [S5](#SM6){ref-type="supplementary-material"}**). Considering 5S rRNA is more prone to be lost during RNA purification, we calculated the ratio of unprocessed 23S-5S rRNA by dividing the levels of 23S-5S rRNA by those of 23S rRNA calibrated with the amplification efficiencies (**Table [5](#T5){ref-type="table"}**). In the absence of AZM, the ratios of unprocessed 23S-5S rRNA were approximately 0.014 and 0.009% in wild type PA14 and the ΔPA3297 mutant, respectively. It seems that, without PA3297, the processing of 23S-5S rRNA is even more efficient. In the presence of 5 and 10 μg/ml AZM, the ratios of unprocessed 23S-5S rRNA rose to approximately 0.05 and 0.09% in wild type PA14, respectively. However, the ratios of unprocessed 23S-5S rRNA in the ΔPA3297 mutant were 0.33 and 1.61%, which were approximately 5- and 18-fold higher than those in PA14 under the same condition (**Table [5](#T5){ref-type="table"}**).

###### 

The ratio of unprocessed 23S-5S rRNA in total 23S rRNA (%).

  Strain    AZM (μg/ml)           
  --------- ------------- ------- -------
  PA14      0.014         0.051   0.089
  ΔPA3297   0.009         0.335   1.608
                                  

The unprocessed 23S-5S rRNA ratios were calculated according to the equation: Ratio = (1+e
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Since, the growth speed of the ΔPA3297 mutant in the presence of 10 μg/ml AZM was similar as that of the wild type PA14 in the presence of 40 μg/ml AZM (**Supplementary Figure [S3](#SM4){ref-type="supplementary-material"}**), we compared the rRNAs levels of the two strains grown under the two conditions. The relative levels of 23S-5S rRNA, total 5S and 23S rRNA in the ΔPA3297 mutant were 150, 55, and 100% of those in the wild type PA14, respectively, indicating a similar rRNA processing status with the two different AZM concentrations. In combination, these results suggest that PA3297 might contribute to rRNA processing in response to AZM. And mutation of PA3297 might impair the biosynthesis of ribosome under AZM treatment, which renders the bacterium more susceptible to AZM.

Discussion
==========

By binding to 23S rRNA in the 50S subunit of bacterial ribosome, AZM blocks polypeptide elongation and diminishes the intracellular pools of aminoacyl-tRNAs ([@B76]; [@B21]; [@B79]). And it has been demonstrated that AZM reduces the expression of *gacA* and the small RNAs *rsmY* and *rsmZ*, as well as quorum sensing genes ([@B32]; [@B55]). And the stationary phase killing by sub-MIC AZM was demonstrated to be correlated with increased outer membrane permeability ([@B26]). Here, we found that mutation of PA3297 intensified the AZM mediated inhibitory effects on pyocyanin production and swarming motility of *P. aeruginosa.* In addition, the PA3297 mutant is more susceptible to oxidative stress in the presence of AZM. During infection, host generated reactive oxygen species (ROS) is an important bacterial killing mechanism. Therefore, inhibition of PA3297 together with the treatment with AZM, might render the bacteria more susceptible to host killing.

The MIC of the ΔPA3297 mutant is a quarter of that of the wild type strain. Consistently, the growth speed of the ΔPA3297 mutant in the presence of 10 μg/ml AZM was similar as that of the wild type strain in the presence of 40 μg/ml AZM (**Supplementary Figure [S3](#SM4){ref-type="supplementary-material"}**). However, in the stationary phase cell killing assay, the survival rate of the ΔPA3297 mutant treated with 10 μg/ml AZM was approximately 20% of that of the wild type strain treated with 40 μg/ml AZM (**Figure [6](#F6){ref-type="fig"}**). Therefore, PA3297 might play a more important role in the survival of stationary phase cells under AZM treatment.

Macrolides and lincosamides bind to the 50S of ribosome and block the NPET ([@B76]). In our experiments, mutation in PA3297 did not alter the bacterial resistance to other antibiotics, including those binding to 30S or other parts of 50S ribosome. In addition, the expression of PA3297 was upregulated by AZM, which was abolished by ribosome protection. Therefore, PA3297 might specifically play a role in bacterial response to macrolides and lincosamides.

PA3297 is also named HrpA, both in PAO1 and PA14 ([@B80]). According to the Profiles from GEO Expression Database at NCBI, the expression level of PA3297 was higher in biofilm than that in planktonic cells ([@B3]). Isolates from CF lungs displayed higher expression levels of PA3297 levels than PAO1 ([@B70]; [@B5]). And artificial medium that mimics CF lung sputum could increase the expression level of PA3297 slightly ([@B19]). In addition, increase of PA3297 expression was also observed in antibiotic-resistant small colony variants ([@B78]). However, the expression level of PA3297 showed a significant decrease in response to airway epithelia or low oxygen conditions ([@B1]; [@B13]). These results indicate that the expression of PA3297 is regulated in response to various environmental stesses.

PA3297 is predicted to locate at the cytoplasmic membrane, with a molecular weight of 149.8 kDa ([@B80]). It belongs to the DExD/H box helicase family. Members of this family have been found to play crucial roles in RNA metabolism and gene regulation ([@B43]; [@B29]; [@B31]; [@B42]; [@B58]). According to NCBI protein blast, there are 81 homologous proteins with identities of 78% or more in other microorganisms. The homolog of PA3297 in *Borrelia burgdorferi* was found to be required for mouse infectivity and tick transmission and involved global gene regulation ([@B63]; [@B54]). Another homolog in *E. coli* was found to be involved in fimbrial biogenesis ([@B35]). The identities they shared with PA3297 are 34 and 49%, respectively. Both of them possess the conserved residues in motif I, motif II, and motif III. Meanwhile, they are also involved in RNA processing. In *Listeria monocytogenes*, it has been reported that defect of a DExD-box RNA helicase, Lmo1722, reduced the maturation of 23S RNA ([@B4]) at low temperatures.

In *E. coli*, the primary transcript rRNA is cleaved by RNase III, yielding precursors of the 16S rRNA (17S rRNA), 23S rRNA, and 5S rRNA (9S rRNA; [@B65]). Mutation of RNase III led to slower growth rate, reduction in cell viability and protein synthesis rates in the presence of AZM ([@B66]). In *E. coli*, under certain stress conditions, DEAD box helicase may substitute for RhlB in the degradosome, such as CsdA under cold shock conditions ([@B57]). We found that mutation of PA3297 increased the percentage of unprocessed 23S-5S rRNA in the presence of AZM, which indicates that the cleaving function of RNase III might be impaired under the stress caused by AZM. Therefore, PA3297 might assist RNase III in rRNA processing in the presence of AZM. In addition, although the growth speed and rRNA processing in the ΔPA3297 mutant treated with 10 μg/ml AZM were similar to those in the wild type strain treated with 40 μg/ml AZM (**Supplementary Figure [S3](#SM4){ref-type="supplementary-material"}**), the survival rate of the ΔPA3297 mutant was lower than that of the wild type strain under those conditions. Thus, PA3297 might play other roles in counteracting the effects of AZM.

Overall, mutation of PA3297 renders *P. aeruginosa* more susceptible to AZM mediated inhibition on virulence factors and killing effect. Therefore, targeting the regulatory pathway or the function of PA3297 might further increase the beneficial effects of AZM in the treatment of chronic *P. aeruginosa* infections.
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